Ftt in bioshares, page-4

Lol. Good on David Blake. Thats the kind of financial analyst and observer we need in Ausbio - sticking his neck out just a teensy bit.

Tentatively backing a biotech with imminent trial results is akin to calling a speculative hedge on banking stocks in the face of a royal commission. Just enough conviction for plausible deniability of sentiment..or to be able to say 'I told you so'. Not worth anything until Bioshares index goes overweight FTT.